Devonian Announces the Signing of a Non-Binding Letter of Intent with Folia Biotech to develop FB-631 in cancer immunotherapy

Biotech Investing

Devonian Health Group (TSXV:GSD) and Folia Biotech today announce the signing of a non-binding Letter of Intent to exclusively negotiate the terms establishing an immune-oncology strategic collaboration focused on the development of FB-631 as an immunotherapeutic platform. As quoted in the press release: The discussions pertain to form a strategic alliance with Folia Biotech Inc. to …

Devonian Health Group (TSXV:GSD) and Folia Biotech today announce the signing of a non-binding Letter of Intent to exclusively negotiate the terms establishing an immune-oncology strategic collaboration focused on the development of FB-631 as an immunotherapeutic platform.

As quoted in the press release:

The discussions pertain to form a strategic alliance with Folia Biotech Inc. to develop the technology in cancer immunotherapy. FB-631 is a nanoparticle made of the recombinant coat protein (CP) of papaya mosaic virus (PapMV) self-assembled around as ssRNA that is used as a toll like receptor 7/8 agonist and intended to activate innate immunity and enhance the human anti-cancer immune response. This platform can find applications in cancer immunotherapy as well as in the development of vaccines to infectious diseases.

“We are excited about the potential to work with Folia,” said Dr Andre P. Boulet, President and Chief Executive Officer of Devonian. “Folia’s cancer immunotherapy, FB-631, has the potential to compete actual Cart-t-cell therapy against solid and non-solid tumors. This product would add another immune-modulator product in our pipeline’’ added Dr Boulet.

“This partnership is a really exciting opportunity to push one step forward the development of our platform technology’ said Dr Denis Leclerc, the founder of Folia Biotech inc and the inventor of the technology. We believe that we will make rapid progress in the treatment of leukemia in children, which will establish our proof of concept in cancer immunotherapy that will lead us to treat other form of cancers”.

Click here to read the full press release.

The Conversation (0)
×